Chapter

Systemic treatment: immunotherapy

Bernard Escudier, Marine Gross Goupil, Christophe Massard and Karim Fizazi

in Renal Cancer

Published on behalf of Oxford University Press

ISBN: 9780199562312
Published online September 2011 | e-ISBN: 9780199607402 | DOI: http://dx.doi.org/10.1093/med/9780199562312.003.0006

Series: Oxford Oncology Library

Systemic treatment: immunotherapy

Show Summary Details

Preview

• For 20 years, immunotherapy has been the standard of care for renal cell carcinoma (RCC) • Although the new targeted therapies have dramatically changed the landscape of this disease, immunotherapy remains an attractive therapeutic option in this disease • Initially, there have been two main reasons for developing immunotherapy in RCC • The resistance to any kind of chemotherapy • The observation that spontaneous remission was observed in this disease, strongly suggesting the role of immune system • The enthusiasm for immunotherapy was then greatly stimulated by the initial results of high-dose interleukin 2 (IL-2), demonstrating a significant proportion of patients achieving partial or even complete remission, with sustained responses and long-lasting responses. Furthermore, the first results with the use of interferon (IFN) confirmed that responses could be observed with cytokines • These exciting data stimulated research in the field of immunology and immunotherapy of RCC, and led to the attempt to treat the disease with different types of immune manipulations, including cell therapy, vaccines, and bone marrow transplantation.

Chapter.  3839 words. 

Subjects: Clinical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.